Last updated: February 13, 2026
What is the current market status for NDC 54766-0590?
NDC 54766-0590 is identified as a biosimilar product, specifically a biosimilar for trastuzumab, marketed under the name Herzuma (or equivalent in different regions). It entered the U.S. market after receiving FDA approval in 2018. As a biosimilar, the drug aims to provide a cost-effective alternative to the reference biologic Herceptin (trastuzumab).
The biosimilar has grown in uptake, driven by payor policies favoring cost reduction, provider acceptance, and wide insurance coverage. Sales have increased from approximately $25 million in 2018 to roughly $730 million in 2022 in the U.S., reflecting its adoption in oncology.
How does the competitive landscape influence pricing?
The biologic and biosimilar markets for trastuzumab face competition primarily from Herceptin (Genentech/Roche) and other biosimilar entrants. The biosimilar market shares position true price competition, with discounts ranging from 15% to 35% below the originator, depending on market dynamics and negotiations.
While original biologics maintain premium pricing—Herceptin's list price in 2022 was around $2,800 per 440 mg vial—biosimilar prices often start around 20-30% below this. Discounting strategies, contracting, and pharmacy benefit manager (PBM) negotiations strongly influence final prices.
What are the projected market trends and price trajectories?
Price projections for NDC 54766-0590 depend on several factors:
-
Patent Eviction and Market Entry: The primary patent for Herceptin expired in 2019, allowing additional biosimilar competitors to enter the market, intensifying price competition.
-
Market Penetration: Biosimilar market share is expected to reach 50-60% by 2025, supported by policy incentives and expanding clinician familiarity.
-
Pricing Dynamics: Biosimilar prices are projected to decrease by an additional 10-15% annually through 2025 due to increased competition and decreasing manufacturing costs.
| Year |
Estimated Biosimilar Price per 440 mg Vial |
Comments |
| 2023 |
$1,950 - $2,100 |
Initial discount of 20-30% from Herceptin list price |
| 2024 |
$1,700 - $1,850 |
Continued price erosion; increased market share |
| 2025 |
$1,500 - $1,650 |
Further competition, high penetration |
Total sales are projected to grow from current levels due to increased utilization but will be constrained by reimbursement and contracting strategies that limit price inflation.
How do reimbursement policies affect market and prices?
Medicare Part B, the primary payer for trastuzumab, reimburses at a percentage of the Average Sales Price (ASP) plus 6%. The shift toward biosimilars in Part B reimbursement reduces reimbursement levels to biosimilars, incentivizing providers to prescribe biosimilar options over the originator.
Insurers and pharmacy benefit managers may prefer biosimilars due to lower costs, leading to formulary placement that favors biosimilars. This constrains the pricing power of the originator and influences biosimilar pricing.
What are the risks and uncertainties influencing future prices?
-
Regulatory Changes: Future approval pathways or modified biosimilar regulatory policies could impact market entry and pricing.
-
Market Acceptance: Slow adoption by oncologists or patient hesitancy could limit uptake and depress prices.
-
Patent Litigation: Ongoing patent disputes may delay biosimilar penetration, impacting pricing and sales.
-
Manufacturing Costs: Advances in manufacturing could decrease biosimilar costs, enabling further price reductions.
What is the outlook for profitability and investment?
Investments in biosimilar manufacturing capacity and pipeline expansion are expected to continue, with return on investment driven by market share gains. Entry of multiple biosimilars will exert downward pressure on prices but create opportunities for market expansion, especially in emerging markets and hospitals.
Key Takeaways
-
NDC 54766-0590 is a biosimilar for trastuzumab, well-positioned in a market that is rapidly growing and consolidating after patent expiration.
-
Prices are expected to decrease by approximately 10-15% annually through 2025, driven by increased competition and market penetration.
-
Total sales are projected to rise due to greater utilization, but the price erosion will temper revenue growth.
-
Reimbursement policies favor biosimilar uptake, exerting additional downward pressure on prices.
-
Market risks include regulatory changes, slow adoption, patent disputes, and manufacturing costs.
FAQs
Q1: What factors influence biosimilar pricing more than originator biologics?
A1: Competition, policy reforms, reimbursement mechanisms, and negotiated discounts significantly impact biosimilar prices.
Q2: When will biosimilar market share surpass 50%?
A2: projections estimate this will occur around 2024-2025, depending on regional policies and prescriber acceptance.
Q3: How do biosimilar prices compare globally?
A3: Prices are generally lower outside the U.S., with discounts up to 40-50% in some markets due to different pricing regulations.
Q4: Will biosimilars replace originator drugs completely?
A4: Not entirely; they will coexist, with biosimilars focused on cost savings and increased access, particularly in developed countries.
Q5: What is the outlook for innovation in biosimilar development?
A5: Focus shifts toward more complex biologics, needle-to-needle manufacturing, and personalized medicine applications.
References
[1] IQVIA Biotech. "Biosimilar Market Analysis." 2022.
[2] FDA. "Drug Approvals and Labeling." 2018.
[3] GlobalData. "Oncology Biosimilars Market Forecast." 2023.
